Welcome to STN International! Enter x:x

LOGINID: SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
NEWS 1
                Web Page URLs for STN Seminar Schedule - N. America
NEWS 2
                "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4 OCT 03 MATHDI removed from STN
NEWS 5 OCT 04 CA/CAplus-Canadian Intellectual Property Office (CIPO) added
                to core patent offices
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 7 OCT 17
                STN(R) AnaVist(TM), Version 1.01, allows the export/download
                of CAplus documents for use in third-party analysis and
                visualization tools
NEWS 8 OCT 27 Free KWIC format extended in full-text databases
NEWS 9 OCT 27 DIOGENES content streamlined
NEWS 10 OCT 27 EPFULL enhanced with additional content
NEWS 11 NOV 14 CA/Caplus - Expanded coverage of German academic research
NEWS 12 NOV 30
                REGISTRY/ZREGISTRY on STN(R) enhanced with experimental
                spectral property data
NEWS EXPRESS NOVEMBER 18 CURRENT VERSION FOR WINDOWS IS V8.01,
             CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
             AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005.
             V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
             http://download.cas.org/express/v8.0-Discover/
             STN Operating Hours Plus Help Desk Availability
NEWS HOURS
             General Internet Information
NEWS INTER
             Welcome Banner and News Items
NEWS LOGIN
             Direct Dial and Telecommunication Network Access to STN
NEWS PHONE
NEWS WWW
             CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 07:31:13 ON 01 DEC 2005

=> s (HIP (W2) 1) or (huntingtin interacting protein)
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files. For example, the EXPAND
command can only be used to look at the index in a file which has an
index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> s (HIP1) or (HIP-1) or (huntingtin interacting protein)
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files. For example, the EXPAND
command can only be used to look at the index in a file which has an
index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> s (HIP(W)1) or (huntingtin interacting protein)
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files. For example, the EXPAND
command can only be used to look at the index in a file which has an
index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> file medline
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 1.05 1.05

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 07:34:23 ON 01 DEC 2005

FILE LAST UPDATED: 30 NOV 2005 (20051130/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow promt (=>). See also:

http://www.nlm.nih.gov/mesh/ http://www.nlm.nih.gov/pubs/techbull/nd04/nd04 mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s (HIP (W2) 1) or (huntingtin interacting protein)
MISSING OPERATOR 'HIP (W2'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s (HIP(W)1) or (huntingtin interacting protein)

64767 HIP

6658 HIPS

65987 HIP

(HIP OR HIPS)

3594301 1

86 HIP(W)1

949 HUNTINGTIN

4 HUNTINGTINS

949 HUNTINGTIN

(HUNTINGTIN OR HUNTINGTINS)

27050 INTERACTING

1450747 PROTEIN

1203182 PROTEINS

1838970 PROTEIN

L1

(PROTEIN OR PROTEINS)

59 HUNTINGTIN INTERACTING PROTEIN

(HUNTINGTIN (W) INTERACTING (W) PROTEIN)

139 (HIP(W)1) OR (HUNTINGTIN INTERACTING PROTEIN)

```
=> s autoantibod?
        49366 AUTOANTIBOD?
=> s 11 and 12
            1 L1 AND L2
L3
=>
---Logging off of STN---
Executing the logoff script...
=> LOG Y
COST IN U.S. DOLLARS
                                                 SINCE FILE
                                                                 TOTAL
                                                      ENTRY
                                                               SESSION
                                                       0.38
FULL ESTIMATED COST
                                                                  1.43
STN INTERNATIONAL LOGOFF AT 07:35:16 ON 01 DEC 2005
Connecting via Winsock to STN
Welcome to STN International! Enter x:x
LOGINID: SSSPTA1642BJF
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2
* * * * * * * * * * * Welcome to STN International
                 Web Page URLs for STN Seminar Schedule - N. America
NEWS 1
                  "Ask CAS" for self-help around the clock
NEWS 2
NEWS 3 SEP 09
                 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4 OCT 03
                 MATHDI removed from STN
 NEWS 5 OCT 04
                 CA/CAplus-Canadian Intellectual Property Office (CIPO) added
                  to core patent offices
NEWS 6 OCT 13
                 New CAS Information Use Policies Effective October 17, 2005
NEWS 7
         OCT 17
                  STN(R) AnaVist(TM), Version 1.01, allows the export/download
                  of CAplus documents for use in third-party analysis and
                  visualization tools
     8 OCT 27
                  Free KWIC format extended in full-text databases
 NEWS
 NEWS
      9
         OCT 27
                 DIOGENES content streamlined
         OCT 27
 NEWS 10
                 EPFULL enhanced with additional content
 NEWS 11
         NOV 14
                  CA/CAplus - Expanded coverage of German academic research
 NEWS 12
         NOV 30
                  REGISTRY/ZREGISTRY on STN(R) enhanced with experimental
                  spectral property data
NEWS EXPRESS NOVEMBER 18 CURRENT VERSION FOR WINDOWS IS V8.01,
              CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
              AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005.
              V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
              http://download.cas.org/express/v8.0-Discover/
```

```
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 07:36:33 ON 01 DEC 2005

=> file medline COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 07:36:44 ON 01 DEC 2005

FILE LAST UPDATED: 30 NOV 2005 (20051130/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow promt (=>). See also:

http://www.nlm.nih.gov/mesh/ http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s (HIP (w) 1) or (huntingtin interacting protein) 64767 HIP

6658 HIPS

65987 HIP

(HIP OR HIPS)

3594301 1

86 HIP (W) 1

949 HUNTINGTIN

4 HUNTINGTINS

949 HUNTINGTIN

(HUNTINGTIN OR HUNTINGTINS)

27050 INTERACTING

1450747 PROTEIN

1203182 PROTEINS

1838970 PROTEIN

(PROTEIN OR PROTEINS)

59 HUNTINGTIN INTERACTING PROTEIN

(HUNTINGTIN (W) INTERACTING (W) PROTEIN)

139 (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)

```
=> s autoantibod? or (anti () antibod?)
         49366 AUTOANTIBOD?
        583989 ANTI
             6 ANTIS
        583993 ANTI
                 (ANTI OR ANTIS)
        701293 ANTIBOD?
           222 ANTI (W) ANTIBOD?
L2
         49578 AUTOANTIBOD? OR (ANTI (W) ANTIBOD?)
=> s 12 and 11
            1 L2 AND L1
=> s humoral
         32817 HUMORAL
             1 HUMORALS
         32818 HUMORAL
L4
                 (HUMORAL OR HUMORALS)
=> s 14 and 11
            0 L4 AND L1
L5
=> s elicit (S) antibod?
         26267 ELICIT
          9942 ELICITS
         35347 ELICIT
                 (ELICIT OR ELICITS)
        701293 ANTIBOD?
         2204 ELICIT (S) ANTIBOD?
L6
=> s 16 and 11
             0 L6 AND L1
L7
=> s antibod?
       701293 ANTIBOD?
=> s serum or sera or blood or urine or sample
MISSING TERM AFTER URINE OR
Operators must be followed by a search term, L-number, or query name.
=> s serum or sera or blood or urine
        575020 SERUM
          4920 SERUMS
        118207 SERA
            14 SERAS
        652274 SERUM
                 (SERUM OR SERUMS OR SERA OR SERAS)
        118207 SERA
            14 SERAS
        118216 SERA
                 (SERA OR SERAS)
       2148697 BLOOD
           618 BLOODS
       2148798 BLOOD
                 (BLOOD OR BLOODS)
        235236 URINE
          2707 URINES
        235631 URINE
                 (URINE OR URINES)
ь9
       2566559 SERUM OR SERA OR BLOOD OR URINE
=> s 19 (S) 18
L10 94348 L9 (S) L8
```

=> s 110 and 11

L11 2 L10 AND L1

=> d ibib 1-2

L11 ANSWER 1 OF 2 MEDLINE on STN ACCESSION NUMBER: 2005258409 MEDLINE DOCUMENT NUMBER: PubMed ID: 15899803

TITLE: Serum antibodies to huntingtin interacting protein-1: a new

AUTHOR: blood test for prostate cancer.

Bradley Sarah V; Oravecz-Wilson Katherine I; Bougeard

Gaelle; Mizukami Ikuko; Li Lina; Munaco Anthony J;

Sreekumar Arun; Corradetti Michael N; Chinnaiyan Arul M;

Sanda Martin G; Ross Theodora S

CORPORATE SOURCE: Department of Internal Medicine, University of Michigan

Medical School, Ann Arbor, Michigan 48109-0942, USA.

CONTRACT NUMBER: R01 CA098730-02 (NCI)

R01 CA82419-01 (NCI) R01-CA82363-01A1 (NCI)

SOURCE: Cancer research, (2005 May 15) 65 (10) 4126-33.

Journal code: 2984705R. ISSN: 0008-5472.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200507

ENTRY DATE: Entered STN: 20050519

Last Updated on STN: 20050708 Entered Medline: 20050707

L11 ANSWER 2 OF 2 MEDLINE on STN
ACCESSION NUMBER: 1999408822 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10479128

TITLE: Viral and immunologic examination of human immunodeficiency

virus type 1-infected, persistently seronegative persons.

AUTHOR: Ellenberger D L; Sullivan P S; Dorn J; Schable C; Spira T

J; Folks T M; Lal R B

CORPORATE SOURCE: HIV/AIDS Branch, Centers for Disease Control and

Prevention, Atlanta, GA 30333, USA.. dxel@cdc.gov

SOURCE: Journal of infectious diseases, (1999 Oct) 180 (4) 1033-42.

Journal code: 0413675. ISSN: 0022-1899.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals; AIDS

ENTRY MONTH: 199911

ENTRY DATE: Entered STN: 20000111

Last Updated on STN: 20000111 Entered Medline: 19991108

=> d ibib kwic 2

L11 ANSWER 2 OF 2 MEDLINE on STN ACCESSION NUMBER: 1999408822 MEDLINE DOCUMENT NUMBER: PubMed ID: 10479128

TITLE: Viral and immunologic examination of human immunodeficiency

virus type 1-infected, persistently seronegative persons.

AUTHOR: Ellenberger D L; Sullivan P S; Dorn J; Schable C; Spira T

J; Folks T M; Lal R B

CORPORATE SOURCE: HIV/AIDS Branch, Centers for Disease Control and

Prevention, Atlanta, GA 30333, USA.. dxe1@cdc.gov

SOURCE: Journal of infectious diseases, (1999 Oct) 180 (4) 1033-42.

Journal code: 0413675. ISSN: 0022-1899.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals; AIDS

ENTRY MONTH: 199911

ENTRY DATE: Entered STN: 20000111

Last Updated on STN: 20000111 Entered Medline: 19991108

AB . . . (HIV-1)-infected but who remained persistently seronegative (HIPS) on HIV-1 antibody tests were examined through AIDS case surveillance. Six such individuals (HIPS-1 to -4, -7, and -9) were examined to determine whether their persistent seronegativity was attributable to immune dysfunction or infection. . . HIV. Of the 6, 4 had antibody titers to at least 1 other common pathogen. In vitro stimulation of peripheral blood mononuclear cells from HIPS-4 and HIPS-7 with pokeweed mitogen or phosphorothioate oligodeoxynucleotide (direct B cell mitogen) did not produce HIV-1-specific antibody. Reconstitution experiments with recombinant interleukin (rIL)-4 and rIL-12 also had no impact on antibody production. Virus isolates from HIPS-4

=> file caplus
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL ENTRY SESSION 2.46 2.67

FILE 'CAPLUS' ENTERED AT 07:39:59 ON 01 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Dec 2005 VOL 143 ISS 23 FILE LAST UPDATED: 30 Nov 2005 (20051130/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

8477265 1

67 HIP (W) 1 999 HUNTINGTIN

83 HUNTINGTINS

1015 HUNTINGTIN

(HUNTINGTIN OR HUNTINGTINS)

```
77642 INTERACTING
       1810847 PROTEIN
       1263057 PROTEINS
       2105815 PROTEIN
                 (PROTEIN OR PROTEINS)
           113 HUNTINGTIN INTERACTING PROTEIN
                 (HUNTINGTIN (W) INTERACTING (W) PROTEIN)
           173 (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)
L12
=> s autoantibod? or (anti () antibod?)
         17882 AUTOANTIBOD?
        388917 ANTI
             9 ANTIS
        388924 ANTI
                 (ANTI OR ANTIS)
        448177 ANTIBOD?
           211 ANTI (W) ANTIBOD?
         18079 AUTOANTIBOD? OR (ANTI (W) ANTIBOD?)
L13
=> s 112 and 113
L14
            1 L12 AND L13
=> s elicit (S) antibod?
         21152 ELICIT
          8791 ELICITS
         29177 ELICIT
                 (ELICIT OR ELICITS)
        448177 ANTIBOD?
          2567 ELICIT (S) ANTIBOD?
L15
=> s antibod?
       448177 ANTIBOD?
L16
=> s serum or sera or blood or urine
        537399 SERUM
         16738 SERUMS
         45362 SERA
             9 SERAS
        561377 SERUM
                 (SERUM OR SERUMS OR SERA OR SERAS)
         45362 SERA
             9 SERAS
         45368 SERA
                 (SERA OR SERAS)
       1216021 BLOOD
          1208 BLOODS
       1216155 BLOOD
                 (BLOOD OR BLOODS)
        207583 URINE
          4423 URINES
        208004 URINE
                  (URINE OR URINES)
       1569955 SERUM OR SERA OR BLOOD OR URINE
L17
=> s 116 (S) 117
         71367 L16 (S) L17
L18
=> s 118 and 112
             3 L18 AND L12
=> d ibib 1-3
L19 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
```

2005:430537 CAPLUS

ACCESSION NUMBER:

DOCUMENT NUMBER: 143:94728

TITLE: Serum antibodies to Huntingtin interacting

protein-1: A new blood test for

prostate cancer

AUTHOR(S): Bradley, Sarah V.; Oravecz-Wilson, Katherine I.;

Bougeard, Gaelle; Mizukami, Ikuko; Li, Lina; Munaco, Anthony J.; Sreekumar, Arun; Corradetti, Michael N.; Chinnaiyan, Arul M.; Sanda, Martin G.; Ross, Theodora

s.

CORPORATE SOURCE: Department of Internal Medicine, University of

Michigan Medical School, Ann Arbor, MI, USA

SOURCE: Cancer Research (2005), 65(10), 4126-4133

CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal LANGUAGE: English

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:417568 CAPLUS

DOCUMENT NUMBER: 139:5159

TITLE: Overexpressed in cancer of huntingtin

interacting protein, HIP1,

antibodies, HIP1-encoding nucleic acids, and

diagnostic and therapeutic uses

INVENTOR(S): Ross, Theodora; Mizukami, Ikuko; Roa, Dinesh

PATENT ASSIGNEE(S): The Regents of the University of Michigan, USA

SOURCE: PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.					KIND		DATE		APPLICATION NO.					DATE			
	WO 2003043566 WO 2003043566				A2 20030530 A3 20050303		WO 2002-US36175					20021112					
	W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
		co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PH,	PL,
		PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	TZ,	UA,	ŪĠ,
		US,	UZ,	VN,	YU,	ZA,	zw										
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
		KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,
		FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	SK,	TR,	BF,	ВJ,	CF,
		CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG			
US 2003124533				A1 20030703			US 2001-7047					20011206					
CA	4 2467459				AA 20030530			CA 2002-2467459					20021112				
EP	1527	190			A2		2005	0504		EP 2	002-	7939:	14		2	0021	112
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
		IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,				
US	2004265929				A1 20041230			US 2004-767325				20040129					
WO	2005072457				A2 20050811				WO 2005-US3330				20050128				
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
		GE,	GH,	GM,	HR,	ΗU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KZ,	LC,
		•	•	•	•		•		•	MG,	•	•	•	•	•	•	•
		•	•	•	•	•	•		•	RU,	•	•	•	•		•	•
		•	•	•	•	•		•	•	US,	•	•	•	•	•	•	
	RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,

```
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                            US 2001-335276P
                                                                Ρ
                                                                   20011115
                                            US 2001-7047
                                                                A 20011206
                                                                W
                                            WO 2002-US36175
                                                                   20021112
                                            US 2004-767325
                                                                A 20040129
L19 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:
                         1999:668929 CAPLUS
DOCUMENT NUMBER:
                         132:150503
TITLE:
                         Viral and immunologic examination of human
                         immunodeficiency virus type 1-infected, persistently
                         seronegative persons
                         Ellenberger, Dennis L.; Sullivan, Patrick S.; Dorn,
AUTHOR(S):
                         Jonathan; Schable, Charles; Spira, Thomas J.; Folks,
                         Thomas M.; Lal, Renu B.
                         HIV/AIDS and Retrovirology Branch, Division of AIDS,
CORPORATE SOURCE:
                         STD, and TB Laboratory Research, National Center for,
                         Atlanta, GA, 30333, USA
SOURCE:
                         Journal of Infectious Diseases (1999), 180(4),
                         1033-1042
                         CODEN: JIDIAQ; ISSN: 0022-1899
                         University of Chicago Press
PUBLISHER:
DOCUMENT TYPE:
                         Journal
                         English
LANGUAGE:
                               THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS
                         36
REFERENCE COUNT:
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
=> d kwic 2
L19 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
TI
     Overexpressed in cancer of huntingtin interacting
     protein, HIP1, antibodies, HIP1-encoding nucleic acids, and
     diagnostic and therapeutic uses
ST
     overexpression cancer huntingtin interacting
     protein HIP1 tumor marker; diagnosis anticancer prostate colon
     cancer HIP1
IT
     Animal cell line
        (3T3, NIH/3T3, HIP1 has oncogenic activities in; overexpressed in
        cancer of huntingtin interacting protein,
        HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and
        therapeutic uses)
     Hybridoma
TΤ
        (ATCC PTA-3901, PTA-3902, PTA-4071; overexpressed in cancer of
        huntingtin interacting protein, HIP1,
        antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
        uses)
     Animal cell line
IT
        (Colo 205, use in drug screening; overexpressed in cancer of
        huntingtin interacting protein, HIP1,
        antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
ΙT
     Nucleic acid hybridization
        (DNA-mRNA, in situ; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
ΙT
     Protein motifs
        (ENTH domain, of HIP1, prospective drug binds to; overexpressed in
        cancer of huntingtin interacting protein,
        HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and
```

therapeutic uses)

```
TT
     Proteins
     RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
     unclassified); DGN (Diagnostic use); PRP (Properties); BIOL (Biological
     study); USES (Uses)
        (HIP1 (huntingin interacting protein 1); overexpressed in cancer of
        huntingtin interacting protein, HIP1,
        antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
        uses)
IT
    Mus
        (HIP1 knockout, model, use in drug screening; overexpressed in cancer
        of huntingtin interacting protein, HIP1,
        antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
        uses)
    Transformation, neoplastic
IT
        (HIP1 role in; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
TΤ
     Gene, animal
     RL: ANT (Analyte); BUU (Biological use, unclassified); DGN (Diagnostic
     use); PRP (Properties); REM (Removal or disposal); ANST (Analytical
     study); BIOL (Biological study); PROC (Process); USES (Uses)
        (HIP1, knock-out; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
IT
     Proteins
     RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
     (Uses)
        (HIP1, mutant, with ENTH-domain deletion; overexpressed in cancer of
        huntingtin interacting protein, HIP1,
        antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
        uses)
     Probes (nucleic acid)
TT
     RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical
     study); BIOL (Biological study); USES (Uses)
        (HIP1-specific; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
ፐጥ
     RL: ADV (Adverse effect, including toxicity); ANT (Analyte); DGN
     (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES
     (Uses)
        (HIP1; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
     Antibodies and Immunoglobulins
     RL: ARG (Analytical reagent use); DGN (Diagnostic use); THU (Therapeutic
     use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
        (HIP1; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
     Antisense nucleic acids
ΙT
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (HIP1; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
     PCR (polymerase chain reaction)
IT
        (RT-PCR (reverse transcription-PCR); overexpressed in cancer of
        huntingtin interacting protein, HIP1,
        antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
        uses)
ΤТ
     Epidermal growth factor receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (activated by HIP1; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
```

```
nucleic acids, and diagnostic and therapeutic uses)
ΙT
    Blood plasma
      Blood serum
        (anal.; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies,
        HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)
Τጥ
    Lipids, biological studies
    RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (analogs, library, screening; overexpressed in cancer of
        huntingtin interacting protein, HIP1,
        antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
        uses)
IT
    Prostate gland, disease
        (benign hyperplasia; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
       nucleic acids, and diagnostic and therapeutic uses)
    Hyperplasia
IΤ
        (benign prostatic; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
       nucleic acids, and diagnostic and therapeutic uses)
IT
    Apoptosis
        (cancer cell, induction; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
IT
    Diagnosis
        (cancer; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
TΤ
     Prostate gland, neoplasm
        (carcinoma, metastasis; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
IT
     Prostate gland, neoplasm
        (carcinoma; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
IT
    Intestine
        (colon, epithelium, HIP1 absent in normal; overexpressed in cancer of
        huntingtin interacting protein, HIP1,
        antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
        uses)
    Intestine, neoplasm
IT
        (colon; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
ΙT
     Epithelium
        (colonic, HIP1 absent in normal; overexpressed in cancer of
        huntingtin interacting protein, HIP1,
        antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
        uses)
ΙT
    Fibroblast
        (embryonic, mouse, use in drug screening; overexpressed in cancer of
        huntingtin interacting protein, HIP1,
        antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
        uses)
IT
     Prostate gland
        (epithelium, HIP1 absent in normal; overexpressed in cancer of
        huntingtin interacting protein, HIP1,
        antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
        uses)
IT
    DNA sequences
        (for ENTH-domain deletion-containing HIP1 protein; overexpressed in cancer
```

of huntingtin interacting protein, HIP1,

```
antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
        uses)
IT
     Gene targeting
        (gene knock-out, of HIP1 gene; overexpressed in cancer of
        huntingtin interacting protein, HIP1,
        antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
        uses)
IT
     Prostate gland, neoplasm
        (identifying stage of; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
IT
     Cell proliferation
        (inhibition, cancer; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
     Prostate gland, neoplasm
IT
        (intraepithelial, high-grade; overexpressed in cancer of
        huntingtin interacting protein, HIP1,
        antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
IT
     Phosphatidylinositols
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (mimetics; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
ΙT
     Diagnosis
        (mol., cancer; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
     Antibodies and Immunoglobulins
TΤ
     RL: ARG (Analytical reagent use); DGN (Diagnostic use); THU (Therapeutic
     use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
        (monoclonal, HIP1; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
     Protein sequences
TT
        (of ENTH-domain deletion-containing HIP1 protein; overexpressed in cancer
        of huntingtin interacting protein, HIP1,
        antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
        uses)
     Antitumor agents
TТ
       Blood analysis
     Carcinoma
     DNA microarray technology
     Drug screening
     Human
     Mus
     Northern blot hybridization
     Nucleic acid hybridization
     Susceptibility (genetic)
     Test kits
     Tumor markers
       Urine analysis
        (overexpressed in cancer of huntingtin interacting
        protein, HIP1, antibodies, HIP1-encoding nucleic
        acids, and diagnostic and therapeutic uses)
ΙT
     Prognosis
        (progression of prostate cancer; overexpressed in cancer of
        huntingtin interacting protein, HIP1,
        antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
        uses)
IT
     Epithelium
        (prostatic, HIP1 absent in normal; overexpressed in cancer of
        huntingtin interacting protein, HIP1,
```

```
antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
        uses)
IT
     Carcinoma
        (prostatic, metastasis; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
ΙT
     Carcinoma
        (prostatic; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
TΤ
     Peptide library
        (screening; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
TΤ
    Animal tissue
        (tumor, anal.; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
IT
     532767-22-9
     RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); THU
     (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES
        (amino acid sequence; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
     532767-21-8
TT
     RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
        (amino acid sequence; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
     532767-23-0
     RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); THU
     (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES
     (Uses)
        (nucleotide sequence; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
IT
     532767-20-7
     RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
        (nucleotide sequence; overexpressed in cancer of huntingtin
        interacting protein, HIP1, antibodies, HIP1-encoding
        nucleic acids, and diagnostic and therapeutic uses)
                  532770-65-3, 6: PN: WO03043566 SEQID: 6 unclaimed DNA
TΥ
     532770-64-2
     RL: PRP (Properties)
        (unclaimed nucleotide sequence; overexpressed in cancer of
        huntingtin interacting protein, HIP1,
        antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic
        uses)
=> d ibib 2
L19 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
                         2003:417568 CAPLUS
ACCESSION NUMBER:
DOCUMENT NUMBER:
                         139:5159
                         Overexpressed in cancer of huntingtin
TITLE:
                         interacting protein, HIP1,
                         antibodies, HIP1-encoding nucleic acids, and
                         diagnostic and therapeutic uses
                         Ross, Theodora; Mizukami, Ikuko; Roa, Dinesh
INVENTOR(S):
PATENT ASSIGNEE(S):
                         The Regents of the University of Michigan, USA
```

PCT Int. Appl., 143 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE					
WO 2003043566 WO 2003043566	A2 20030530 A3 20050303	WO 2002-US36175	20021112					
W: AE, AG, AL, CO, CR, CU,	AM, AT, AU, AZ, CZ, DE, DK, DM,	BA, BB, BG, BR, BY, DZ, EC, EE, ES, FI, JP, KE, KG, KP, KR,	GB, GD, GE, GH,					
PT, RO, RU, US, UZ, VN,	SD, SE, SG, SI, YU, ZA, ZW	MK, MN, MW, MX, MZ, SK, SL, TJ, TM, TR,	TT, TZ, UA, UG,					
KG, KZ, MD, FI, FR, GB,	RU, TJ, TM, AT, GR, IE, IT, LU,	SL, SZ, TZ, UG, ZM, BE, BG, CH, CY, CZ, MC, NL, PT, SE, SK,	DE, DK, EE, ES,					
US 2003124533	A1 20030703		TG 20011206					
CA 2467459 EP 1527190	AA 20030530 A2 20050504	EP 2002-793914	20021112 20021112					
IE, SI, LT,	LV, FI, RO, MK,	GB, GR, IT, LI, LU, CY, AL, TR, BG, CZ,	EE, SK					
US 2004265929 WO 2005072457	A2 20050811	WO 2005-US3330	20040129 20050128					
CN, CO, CR,	CU, CZ, DE, DK,	BA, BB, BG, BR, BW, DM, DZ, EC, EE, EG, IN, IS, JP, KE, KG,	ES, FI, GB, GD,					
NO, NZ, OM,	PG, PH, PL, PT,	MD, MG, MK, MN, MW, RO, RU, SC, SD, SE, UG, US, UZ, VC, VN,	SG, SK, SL, SY,					
RW: BW, GH, GM, AZ, BY, KG,	KE, LS, MW, MZ, KZ, MD, RU, TJ,	NA, SD, SL, SZ, TZ, TM, AT, BE, BG, CH,	UG, ZM, ZW, AM, CY, CZ, DE, DK,					
	SK, TR, BF, BJ,	IE, IS, IT, LT, LU, CF, CG, CI, CM, GA,						
PRIORITY APPLN. INFO.:		US 2001-335276P US 2001-7047 WO 2002-US36175	P 20011115 A 20011206 W 20021112					
		US 2004-767325	A 20040129					
=> file pctfull COST IN U.S. DOLLARS SINCE FILE TOTAL								
FULL ESTIMATED COST		ENTRY 36.22	SESSION 38.89					

FILE 'PCTFULL' ENTERED AT 07:43:59 ON 01 DEC 2005 COPYRIGHT (C) 2005 Univentio

FILE LAST UPDATED: 22 NOV 2005 <20051122/UP>
MOST RECENT UPDATE WEEK: 200546 <200546/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> KWIC format free of charge - SEE NEWS >>>

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE http://www.stn-international.de/stndatabases/details/ipc_reform.html <

=> s (HIP (w) 1) or (huntingtin interacting protein)

```
8220 HIP
          3092 HIPS
         10435 HIP
                (HIP OR HIPS)
        959046 1
           116 HIP (W) 1
           435 HUNTINGTIN
             6 HUNTINGTINS
           436 HUNTINGTIN
                 (HUNTINGTIN OR HUNTINGTINS)
         36344 INTERACTING
        127255 PROTEIN
        107382 PROTEINS
        140473 PROTEIN
                 (PROTEIN OR PROTEINS)
           106 HUNTINGTIN INTERACTING PROTEIN
                 (HUNTINGTIN (W) INTERACTING (W) PROTEIN)
L20
           203 (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)
=> s autoantibod? or (anti () antibod?)
          2743 AUTOANTIBOD?
        164947 ANTI
           165 ANTIS
        164978 ANTI
                 (ANTI OR ANTIS)
         82883 ANTIBOD?
           883 ANTI (W) ANTIBOD?
L21
          3564 AUTOANTIBOD? OR (ANTI (W) ANTIBOD?)
=> s elicit (S) antibod?
         21422 ELICIT
          7303 ELICITS
         24440 ELICIT
                 (ELICIT OR ELICITS)
         82883 ANTIBOD?
L22
         9992 ELICIT (S) ANTIBOD?
=> s antibod?
    82883 ANTIBOD?
L23
=> s serum or sera or blood or urine
         83318 SERUM
          1356 SERUMS
         45571 SERA
        113532 SERUM
                 (SERUM OR SERUMS OR SERA)
         45571 SERA
            43 SERAS
         45585 SERA
                 (SERA OR SERAS)
        122899 BLOOD
           269 BLOODS
        122912 BLOOD
                 (BLOOD OR BLOODS)
         25180 URINE
           405 URINES
         25292 URINE
                 (URINE OR URINES)
        178963 SERUM OR SERA OR BLOOD OR URINE
L24
=> s 120 and 121
L25
            8 L20 AND L21
```

=> s 120/ab

```
663 HIP/AB
           139 HIPS/AB
           776 HIP/AB
                 ((HIP OR HIPS)/AB)
        230754 1/AB
             4 HIP/AB (W) 1/AB
            16 HUNTINGTIN/AB
             1 HUNTINGTINS/AB
            16 HUNTINGTIN/AB
                 ((HUNTINGTIN OR HUNTINGTINS)/AB)
          2054 INTERACTING/AB
         22930 PROTEIN/AB
         13064 PROTEINS/AB
         31025 PROTEIN/AB
                 ((PROTEIN OR PROTEINS)/AB)
             2 HUNTINGTIN INTERACTING PROTEIN/AB
                 ((HUNTINGTIN(W)INTERACTING(W)PROTEIN)/AB)
L26
             6 ((HIP/AB (W) 1/AB) OR (HUNTINGTIN INTERACTING PROTEIN/AB))
=> s 120/clm
          1264 HIP/CLM
        906427 1/CLM
            16 HIP/CLM (W) 1/CLM
            78 HUNTINGTIN/CLM
          6066 INTERACTING/CLM
         47377 PROTEIN/CLM
            12 HUNTINGTIN INTERACTING PROTEIN/CLM
                 ((HUNTINGTIN(W)INTERACTING(W)PROTEIN)/CLM)
L27
            25 ((HIP/CLM (W) 1/CLM) OR (HUNTINGTIN INTERACTING PROTEIN/CLM))
=> s 126 or 127
            28 L26 OR L27
=> s 128 and 121
             0 L28 AND L21
L29
=> s 123 (S) 124
L30
         41122 L23 (S) L24
=> s (detect? or determin?) (S) 123
        313247 DETECT?
        516096 DETERMIN?
         55958 (DETECT? OR DETERMIN?) (S) L23
L31
=> 131 and 128
L31 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
=> s 131 and 128
L32
           14 L31 AND L28
=> s 132 not py>2003
        222501 PY>2003
            10 L32 NOT PY>2003
L33
=> s cancer? or tumor or neoplas?
         73267 CANCER?
         52062 TUMOR
         32865 TUMORS
         57617 TUMOR
                  (TUMOR OR TUMORS)
         21140 NEOPLAS?
```

```
L34
        89447 CANCER? OR TUMOR OR NEOPLAS?
=> s 133 and 134
           8 L33 AND L34
L35
\Rightarrow s 131/clm
       107933 DETECT?/CLM
        158306 DETERMIN?/CLM
         32513 ANTIBOD?/CLM
L36
         12578 ((DETECT?/CLM OR DETERMIN?/CLM) (S) (ANTIBOD?/CLM))
=> s 136 and 135
T.37
            5 L36 AND L35
=> s 137 and 127
L38
         4 L37 AND L27
=> d ibib 1-4
      ANSWER 1 OF 4
                       PCTFULL COPYRIGHT 2005 Univentio on STN
                       2003043566 PCTFULL ED 20030610 EW 200322
ACCESSION NUMBER:
                      HIP1 CANCER MARKERS
TITLE (ENGLISH):
TITLE (FRENCH):
                       MARQUEURS DE CANCER HIP1
                       ROSS, Theodora, 4870 Lytham Lane, Ann Arbor, MI 48203,
INVENTOR(S):
                       US [US, US];
                       MIZUKAMI, Ikuko, 5225 Earhart Road, Ann Arbor, MI
                        48105, US [US, US];
                        ROA, Dinesh, 2045 Arbor Circle, W., Apt. 102,
                        Ypsilanti, MI 48197, US [US, US]
PATENT ASSIGNEE(S):
                        THE REGENTS OF THE UNIVERSITY OF MICHIGAN, 3003 S.
                        State Street, Ann Arbor, MI 48109, US [US, US], for all
                        designates States except US;
                        ROSS, Theodora, 4870 Lytham Lane, Ann Arbor, MI 48203,
                        US [US, US], for US only;
                        MIZUKAMI, Ikuko, 5225 Earhart Road, Ann Arbor, MI
                        48105, US [US, US], for US only;
                        ROA, Dinesh, 2045 Arbor Circle, W., Apt. 102,
                        Ypsilanti, MI 48197, US [US, US], for US only
AGENT:
                        CARROLL, Peter, G.$, Medlen & Carroll, LLP, Suite 350,
                        101 Howard Street, San Francisco, CA 94105$, US
LANGUAGE OF FILING:
                        English
LANGUAGE OF PUBL.:
                        English
DOCUMENT TYPE:
                       Patent
PATENT INFORMATION:
                       NUMBER
                                         KIND
                                                  DATE
                        ______
                        WO 2003043566
                                           A2 20030530
DESIGNATED STATES
                        AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
      W:
                        CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
                        IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
                        MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK
                        SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
                       GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
       RW (ARIPO):
       RW (EAPO):
                       AM AZ BY KG KZ MD RU TJ TM
                       AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC
       RW (EPO):
                       NL PT SE SK TR
                       BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
       RW (OAPI):
                       WO 2002-US36175 A 20021112
APPLICATION INFO .:
                       US 2001-60/335,276
US 2001-10/007,047
                                                20011115
PRIORITY INFO.:
                                                20011206
```

L38 ANSWER 2 OF 4 PCTFULL COPYRIGHT 2005 Univentio on STN ACCESSION NUMBER: 2000055633 PCTFULL ED 20020515

TITLE (ENGLISH): NOVEL METHODS OF DIAGNOSING COLORECTAL CANCER

, COMPOSITIONS, AND METHODS OF SCREENING FOR COLORECTAL

CANCER MODULATORS

TITLE (FRENCH): METHODES PERMETTANT DE DIAGNOSTIQUER DU CANCER

COLO-RECTAL, COMPOSITIONS, ET METHODES PERMETTANT DE

DETECTER DES MODULATEURS DU CANCER

COLO-RECTAL

INVENTOR(S): MACK, David; GISH, Kurt, C.;

WILSON, Keith, E.

PATENT ASSIGNEE(S): EOS BIOTECHNOLOGY, INC.

LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE
-----WO 2000055633 A2 20000921

DESIGNATED STATES

W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW

ML MR NE SN TD TG

APPLICATION INFO.: PRIORITY INFO.:

 WO
 2000-US7044
 A
 20000315

 US
 1999-09/268,866
 19990315

 US
 1999-09/436,983
 19991109

 US
 1999-09/435,945
 19991109

 US
 1999-09/450,857
 19991129

 US
 1999-09/453,850
 19991202

 US
 2000-09/493,444
 20000128

L38 ANSWER 3 OF 4

ACCESSION NUMBER:

PCTFULL COPYRIGHT 2005 Univentio on STN

2000055629 PCTFULL ED 20020515

TITLE (ENGLISH): NOVEL METHODS OF DIAGNOSING AND TREATING BREAST CANCER, COMPOSITIONS, AND METHODS OF SCREENING

FOR BREAST CANCER MODULATORS

TITLE (FRENCH):

NOUVELLES TECHNIQUES PERMETTANT DE TRAITER ET DE DIAGNOSTIQUER LE CANCER DU SEIN, COMPOSITIONS ET TECHNIQUES DE CRIBLAGE POUR MODULATEURS DE

CANCER DU SEIN

INVENTOR(S): MACK, David;

GISH, Kurt, C.

PATENT ASSIGNEE(S): EOS BIOTECHNOLOGY, INC.;

MACK, David; GISH, Kurt, C.

LANGUAGE OF PUBL.: English DOCUMENT TYPE: Patent

PATENT INFORMATION:

DESIGNATED STATES

W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US6952 A 20000315

PRIORITY INFO.: US 1999-09/268,865 19990315 19991112 19991112 19991115 US 1999-09/439,878 US 1999-09/440,370 US 1999-09/440,493 US 1999-09/440,676 19991116 US 1999-09/440,677 19991116 US 1999-09/450,810 19991129 US 1999-09/453,137 19991202 US 2000-09/453,137 20000308

COPYRIGHT 2005 Univentio on STN ANSWER 4 OF 4 PCTFULL

ACCESSION NUMBER: 1999015626 PCTFULL ED 20020515

TITLE (ENGLISH): IDENTIFICATION OF HOP-1 AND USES THEREOF IDENTIFICATION DE HOP-1 ET SES UTILISATIONS TITLE (FRENCH):

INVENTOR(S): GREENWALD, Iva;

LI, Xiajun

PATENT ASSIGNEE(S): THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW

YORK

LANGUAGE OF PUBL.: English Patent DOCUMENT TYPE:

PATENT INFORMATION:

NUMBER KIND DATE WO 9915626 A1 19990401

DESIGNATED STATES

AU CA JP MX AT BE CH CY DE DK ES FI FR GB GR IE IT LU W:

MC NL PT SE

APPLICATION INFO.: WO 1998-US20030 A 19980925 PRIORITY INFO.: US 1997-08/937,834 19970925 WO 1998-US20030 A 19980925

=> d clm 2

L38 ANSWER 2 OF 4 PCTFULL COPYRIGHT 2005 Univentio on STN

CLM data too large for display

=> d kwic 2

ANSWER 2 OF 4 PCTFULL COPYRIGHT 2005 Univentio on STN L38

NOVEL METHODS OF DIAGNOSING COLORECTAL CANCER, COMPOSITIONS, TIEN AND METHODS OF SCREENING FOR COLORECTAL CANCER MODULATORS

METHODES PERMETTANT DE DIAGNOSTIQUER DU CANCER COLO-RECTAL, TIFR

COMPOSITIONS, ET METHODES PERMETTANT DE DETECTER DES MODULATEURS DU CANCER COLO-RECTAL

Described herein are methods that can be used for diagnosis and ABEN prognosis of colorectal cancer.

Also described herein are methods that can be used to screen candidate bioactive agents for the

ability to modulate colorectal cancer. Additionally, methods

and molecular targets (genes and their products) for therapeutic intervention in colorectal and other

cancers are described. L'invention concerne des methodes utiles pour le diagnostic et le

ABFR pronostic du cancer

colo-rectal. L'invention concerne egalement des methodes permettant de detecter la capacite que

possedent des agents bioactifs candidats pour moduler un cancer colo-rectal. L'invention concerne en

outre des methodes et des cibles moleculaires (genes et leurs produits) permettant d'effectuer une

intervention therapeutique pour lutter contre le cancer colo-rectal et d'autres types cancers.

```
DETD
       data too large for display
       data too large for display
DETD
DETD
       data too large for display
       data too large for display
DETD
DETD
       data too large for display
DETD
       data too large for display
       data too large for display
DETD
DETD
       data too large for display
       data too large for display
DETD
DETD
       data too large for display
       data too large for display
DETD
       data too large for display
DETD
       data too large for display
DETD
DETD
       data too large for display
       data too large for display
DETD
       data too large for display
DETD
DETD
       data too large for display
       data too large for display
DETD
       data too large for display
DETD
```

```
DETD
       data too large for display
DETD
       data too large for display
DETD
       data too large for display
       data too large for display
DETD
DETD
       data too large for display
       data too large for display
DETD
      data too large for display
DETD
DETD
      data too large for display
DETD
      data too large for display
DETD
      data too large for display
DETD
       data too large for display
       data too large for display
DETD
DETD
      data too large for display
DETD
      data too large for display
DETD
      data too large for display
DETD
       data too large for display
DETD
       data too large for display
DETD
       data too large for display
DETD
       data too large for display
DETD
       data too large for display
DETD
       data too large for display
DETD
       data too large for display
DETD
       data too large for display
       data too large for display
DETD
DETD
       data too large for display
       data too large for display
DETD
       data too large for display
DETD
       data too large for display
DETD
       data too large for display
DETD
DETD
       data too large for display
DETD
       data too large for display
       data too large for display
DETD
```

```
DETD
       data too large for display
DETD
       data too large for display
DETD
       data too large for display
       data too large for display
DETD
DETD
       data too large for display
       data too large for display
DETD
       data too large for display
DETD
DETD
       data too large for display
DETD
       data too large for display
DETD
       data too large for display
       data too large for display
DETD
       data too large for display
DETD
DETD
       data too large for display
       data too large for display
DETD
DETD
       data too large for display
DETD
       data too large for display
       data too large for display
DETD
DETD
       data too large for display
DETD
       data too large for display
       data too large for display
DETD
       data too large for display
DETD
CLM
       data too large for display
CLM
       data too large for display
       data too large for display
CLM
       data too large for display
CLM
CLM
       data too large for display
       data too large for display
CLM
CLM
       data too large for display
```

```
CLM
       data too large for display
CLM
      data too large for display
CLM
       data too large for display
       data too large for display
CLM
CLM
       data too large for display
CLM
       data too large for display
      data too large for display
CLM
CLM
      data too large for display
      data too large for display
CLM
CLM
       data too large for display
CLM
       data too large for display
       data too large for display
CLM
CLM
       data too large for display
CLM
       data too large for display
CLM
       data too large for display
       data too large for display
CLM
CLM
       data too large for display
CLM
       data too large for display
CLM
       data too large for display
```

=> file dissab
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL ENTRY SESSION 14.79 53.68

FILE 'DISSABS' ENTERED AT 07:50:33 ON 01 DEC 2005 COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved.

FILE COVERS 1861 TO 23 NOV 2005 (20051123/ED)

Only fair use as provided by the United States copyright law is permitted. PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED MATERIALS OR THEIR USE.

```
=> s (HIP (w) 1) or (huntingtin interacting protein)
1975 HIP
185 HIPS
2094 HIP
(HIP OR HIPS)
```

```
360771 1
             4 HIP (W) 1
            35 HUNTINGTIN
          9222 INTERACTING
         76083 PROTEIN
         41788 PROTEINS
         87948 PROTEIN
                 (PROTEIN OR PROTEINS)
             6 HUNTINGTIN INTERACTING PROTEIN
                 (HUNTINGTIN (W) INTERACTING (W) PROTEIN)
L39
             9 (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)
=> s autoantibod? or (anti () antibod?)
           500 AUTOANTIBOD?
         25594 ANTI
             9 ANTIS
         25599 ANTI
                 (ANTI OR ANTIS)
         19247 ANTIBOD?
             8 ANTI (W) ANTIBOD?
L40
           508 AUTOANTIBOD? OR (ANTI (W) ANTIBOD?)
=> s 139 and 140
             0 L39 AND L40
=> s antibod?
L42
        19247 ANTIBOD?
=> s (detect? or determin?) (S) 142
         81957 DETECT?
        347672 DETERMIN?
          7556 (DETECT? OR DETERMIN?) (S) L42
L43
=> s 143 and 139
L44
             0 L43 AND L39
=> s humoral
         1618 HUMORAL
=> s 145 an d139
MISSING OPERATOR L45 AN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.
=> s 145 and 139
            0 L45 AND L39
L46
=> d his
     (FILE 'HOME' ENTERED AT 07:36:33 ON 01 DEC 2005)
     FILE 'MEDLINE' ENTERED AT 07:36:44 ON 01 DEC 2005
            139 S (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)
L1
          49578 S AUTOANTIBOD? OR (ANTI () ANTIBOD?)
L2
              1 S L2 AND L1
L3
          32818 S HUMORAL
L4
              0 S L4 AND L1
L5
           2204 S ELICIT (S) ANTIBOD?
L6
L7
              0 S L6 AND L1
rs
         701293 S ANTIBOD?
L9
        2566559 S SERUM OR SERA OR BLOOD OR URINE
          94348 S L9 (S) L8
L10
              2 S L10 AND L1
L11
```

```
FILE 'CAPLUS' ENTERED AT 07:39:59 ON 01 DEC 2005
L12
           173 S (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)
L13
          18079 S AUTOANTIBOD? OR (ANTI () ANTIBOD?)
L14
              1 S L12 AND L13
           2567 S ELICIT (S) ANTIBOD?
L15
L16
         448177 S ANTIBOD?
        1569955 S SERUM OR SERA OR BLOOD OR URINE
L17
L18
         71367 S L16 (S) L17
              3 S L18 AND L12
L19
     FILE 'PCTFULL' ENTERED AT 07:43:59 ON 01 DEC 2005
L20
           203 S (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)
L21
           3564 S AUTOANTIBOD? OR (ANTI () ANTIBOD?)
L22
          9992 S ELICIT (S) ANTIBOD?
L23
         82883 S ANTIBOD?
L24
        178963 S SERUM OR SERA OR BLOOD OR URINE
L25
             8 S L20 AND L21
L26
             6 S L20/AB
            25 S L20/CLM
L27
L28
             28 S L26 OR L27
L29
             0 S L28 AND L21
       41122 S L23 (S) L24
55958 S (DETECT) OF
L30
L31
         55958 S (DETECT? OR DETERMIN?) (S) L23
             14 S L31 AND L28
L32
L33
            10 S L32 NOT PY>2003
L34
          89447 S CANCER? OR TUMOR OR NEOPLAS?
             8 S L33 AND L34
L35
          12578 S L31/CLM
L36
              5 S L36 AND L35
L37
L38
              4 S L37 AND L27
     FILE 'DISSABS' ENTERED AT 07:50:33 ON 01 DEC 2005
              9 S (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)
L39
            508 S AUTOANTIBOD? OR (ANTI () ANTIBOD?)
L40
L41
              0 S L39 AND L40
L42
          19247 S ANTIBOD?
L43
           7556 S (DETECT? OR DETERMIN?) (S) L42
L44
              0 S L43 AND L39
L45
           1618 S HUMORAL
            0 S L45 AND L39
L46
=>
---Logging off of STN---
Executing the logoff script...
=> LOG Y
COST IN U.S. DOLLARS
                                                 SINCE FILE
                                                                TOTAL
                                                      ENTRY SESSION 1.23 54.91
FULL ESTIMATED COST
```

STN INTERNATIONAL LOGOFF AT 07:52:08 ON 01 DEC 2005